World's Best Scientists 2026 revealed!
Thomas Valerius

Thomas Valerius

D-Index & Metrics

Immunology

D-Index
50
Citations
9366
World Ranking
4244
National Ranking
282

Overview

Thomas Valerius is affiliated with Kiel University in Germany. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a focus on several interconnected subfields including Immunology, Hematology, Radiology, Nuclear Medicine and Imaging, Oncology, and Public Health, Environmental and Occupational Health.

Their work extensively covers key topics such as Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, CAR-T cell therapy research, Glycosylation and Glycoproteins Research, and Phagocytosis and Immune Regulation.

Valerius has published papers in several frequent venues, including Blood, Frontiers in Immunology, Bone Marrow Transplantation, bioRxiv (Cold Spring Harbor Laboratory), and the Journal for ImmunoTherapy of Cancer.

Selected recent papers include:

  • "Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET" (2021, Journal of Biological Chemistry)
  • "Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity" (2021, Journal of Clinical Investigation)
  • "Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria" (2024, Nature Communications)
  • "Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL" (2022, Blood)
  • "Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages" (2022, Frontiers in Immunology)

Frequent co-authors include Matthias Peipp, Jeanette H.W. Leusen, Thies Rösner, Christian Kellner, and Denis M. Schewe.

Best Publications

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors

    Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker

  • Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

    Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel

  • Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.

    R. Repp;Th. Valerius;A. Sendler;M. Gramatzki

  • Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

    Tanja Schneider-Merck;Jeroen J. Lammerts van Bueren;Sven Berger;Kai Rossen

  • Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.

    Matthias Peipp;Jeroen J. Lammerts van Bueren;Tanja Schneider-Merck;Wim W. K. Bleeker

  • Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.

    Michael Dechant;Wencke Weisner;Sven Berger;Matthias Peipp

  • Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy

    T. Valerius;R. Repp;T. P. M. De Wit;S. Berthold

  • FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

    Thomas Valerius;Bernhard Stockmeyer;Annemiek B. van Spriel;Robert F. Graziano

  • Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.

    Bernhard Stockmeyer;Michael Dechant;Marjolein van Egmond;Alison L. Tutt

  • HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor

    D. Elsässer;T. Valerius;R. Repp;G. J. Weiner

  • Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.

    Joost Neijssen;Rosa M.F. Cardoso;Kristen M. Chevalier;Luus Wiegman

  • Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.

    Arianne M. Brandsma;Sina Bondza;Mitchell Evers;Rosanne Koutstaal

  • Preclinical Studies with FcγR Bispecific Antibodies and Granulocyte Colony-stimulating Factor-primed Neutrophils as Effector Cells against HER-2/neu Overexpressing Breast Cancer

    Bernhard Stockmeyer;Thomas Valerius;Roland Repp;Ingmar A. F. M. Heijnen

  • IgA EGFR antibodies mediate tumour killing in vivo

    Peter Boross;Stefan Lohse;Maaike Nederend;Johannes Hendrik Marco Jansen

  • Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.

    R Repp;H H van Ojik;T Valerius;G Groenewegen

  • Bispecific antibodies targeting cancer cells.

    Matthias Peipp;Thomas Valerius

  • Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.

    Michael Dechant;Gestur Vidarsson;Bernhard Stockmeyer;Roland Repp

  • Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor

    Michael Dechant;Thomas Beyer;Tanja Schneider-Merck;Wencke Weisner

  • FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils

    Louise W. Treffers;Michel van Houdt;Christine W. Bruggeman;Marieke H. Heineke

  • Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

    Würflein D;Dechant M;Stockmeyer B;Tutt Al

  • Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells

    Bernhard Stockmeyer;Thomas Beyer;Winfried Neuhuber;Roland Repp

  • Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

    Joerg Bruenke;Karin Barbin;Susanne Kunert;Peter Lang

  • Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC

    Roland Repp;Christian Kellner;Anja Muskulus;Matthias Staudinger

  • Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.

    Unknown

Frequent Co-Authors

Matthias Peipp
Matthias Peipp Kiel University
Jan G. J. van de Winkel
Jan G. J. van de Winkel Genmab (United States)
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Jeanette H. W. Leusen
Jeanette H. W. Leusen Utrecht University
Martin Schrappe
Martin Schrappe Kiel University
Timo K. van den Berg
Timo K. van den Berg Radboud University
Martin J. Glennie
Martin J. Glennie University of Southampton
Joachim R. Kalden
Joachim R. Kalden University of Erlangen-Nuremberg
Gestur Vidarsson
Gestur Vidarsson University of Amsterdam
Georg H. Fey
Georg H. Fey University of Erlangen-Nuremberg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare and nursing degrees online can open diverse career pathways. Many programs cater specifically to individuals without a nursing background, such as online RN programs for non nurses. These programs provide a streamlined route to becoming a registered nurse, combining foundational healthcare knowledge with specialized skills.

If you are looking for faster entry into the nursing field, some of the easiest accelerated nursing programs are designed to help students quickly earn their Bachelor of Science in Nursing (BSN). These programs often offer flexibility for working professionals or those changing careers.

For a more focused nursing role, easiest LPN programs to get into provide accessible pathways to becoming a Licensed Practical Nurse (LPN), which can serve as a foundation for advancing in nursing or immunology-related fields.

Lastly, to advance clinical expertise and leadership, easiest nurse practitioner program options allow nurses to specialize further and take on more responsibilities in patient care, including immunology-related practices.

Best Scientists Citing Thomas Valerius

Trending Scientists

Recently Published Articles